SOMERSET, N.J., March 9 /PRNewswire-FirstCall/ -- Ventiv Health, Inc. today announced that it has been selected to join the Standard & Poor’s SmallCap 600, effective after the close of trading on Thursday, March 9.
The S&P SmallCap 600 index consists of 600 small-cap stocks, defined as companies with market capitalizations between $300 million and $2 billion. The index was introduced in 1994 in an effort to represent a smaller segment of the market than the S&P MidCap 400 Index. Although it is not yet widely quoted, the S&P SmallCap 600 Index has been gaining popularity among investment managers as an efficient way to track or invest in the small-cap market segment.
Eran Broshy, CEO of Ventiv Health said, “Our addition to the S&P SmallCap 600 happens at a great time in our company’s history. Ventiv has grown through a combination of organic growth and select acquisitions far beyond the company we were only two years ago, and are now positioned as the leading provider of customized clinical, sales, marketing and communications services to the pharmaceutical and biotech industries. We believe that there are opportunities in all areas to continue growing our leadership position. We look forward to the greater visibility and exposure that Ventiv will receive as part of the S&P index.”
About Ventiv Health
Ventiv Health, Inc. is the leading provider of commercialization and complementary services to the global pharmaceutical, life sciences and biotechnology industries. Ventiv delivers its customized clinical, sales, marketing and communications solutions through its three core business segments: Ventiv Clinical, Ventiv Communications and Ventiv Commercial. Ventiv Health works with over 150 pharmaceutical and life sciences clients, including 18 of the top 20 global pharmaceutical companies. For more information, visit www.ventiv.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause Ventiv Health’s performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by Ventiv Health, Inc. with the Securities and Exchange Commission for further discussion of these and other factors.
Ventiv Health, Inc.
CONTACT: Investors/Corporate - John Emery, CFO, Ventiv Health, Inc., +1-732-537-4804, investor@ventiv.com; Media - Felicia Vonella, Ventiv Health,Inc., +1-212-308-7155, fvonella@ventiv.com
Web site: http://www.ventiv.com/
